Ken Ohmachi

932 total citations
46 papers, 599 citations indexed

About

Ken Ohmachi is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Ken Ohmachi has authored 46 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pathology and Forensic Medicine, 23 papers in Oncology and 15 papers in Genetics. Recurrent topics in Ken Ohmachi's work include Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Viral-associated cancers and disorders (10 papers). Ken Ohmachi is often cited by papers focused on Lymphoma Diagnosis and Treatment (29 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Viral-associated cancers and disorders (10 papers). Ken Ohmachi collaborates with scholars based in Japan, United States and Greece. Ken Ohmachi's co-authors include Kiyoshi Ando, Michinori Ogura, Toshiki Uchida, Kensei Tobinai, Yoshiaki Ogawa, Hiroshi Kawada, Naokuni Uike, Ryujiro Hara, Naoya Nakamura and Won Seog Kim and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Ken Ohmachi

45 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ken Ohmachi Japan	13	403	342	211	107	91	46	599
Fiona Miall United Kingdom	13	575 1.4×	435 1.3×	304 1.4×	148 1.4×	171 1.9×	32	758
Alison N. Gencarelli United States	6	431 1.1×	235 0.7×	307 1.5×	90 0.8×	124 1.4×	7	532
Edward Agura United States	10	352 0.9×	332 1.0×	120 0.6×	188 1.8×	102 1.1×	17	621
Magdalena Adde Sweden	5	502 1.2×	385 1.1×	203 1.0×	186 1.7×	75 0.8×	6	630
Jean‐Marc Schiano de Colella France	13	263 0.7×	261 0.8×	99 0.5×	134 1.3×	194 2.1×	41	600
Letizia Gandolfi Italy	13	413 1.0×	196 0.6×	150 0.7×	127 1.2×	66 0.7×	28	504
Sverker Hasselblom Sweden	14	320 0.8×	209 0.6×	115 0.5×	79 0.7×	145 1.6×	25	494
Gaetano Corazzelli Italy	14	493 1.2×	215 0.6×	320 1.5×	333 3.1×	69 0.8×	38	682
Federica Quirini Italy	11	372 0.9×	179 0.5×	116 0.5×	80 0.7×	115 1.3×	17	432
Manuel F. Rosado United States	10	333 0.8×	249 0.7×	97 0.5×	113 1.1×	87 1.0×	14	491

Countries citing papers authored by Ken Ohmachi

Since Specialization

Citations

This map shows the geographic impact of Ken Ohmachi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Ohmachi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Ohmachi more than expected).

Fields of papers citing papers by Ken Ohmachi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Ohmachi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Ohmachi. The network helps show where Ken Ohmachi may publish in the future.

Co-authorship network of co-authors of Ken Ohmachi

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Ohmachi. A scholar is included among the top collaborators of Ken Ohmachi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Ohmachi. Ken Ohmachi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ohmachi, Ken. (2025). JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma5. Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS). International Journal of Hematology. 122(1). 3–16.

Ohmachi, Ken. (2025). JSH practical guidelines for hematological malignancies, 2023: II. lymphoma—overview. International Journal of Hematology. 121(5). 567–576. 1 indexed citations

Shimada, Kazuyuki, Ken Ohmachi, Ryunosuke Machida, et al.. (2024). Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy – a supplementary analysis of JCOG0601. Annals of Hematology. 103(6). 2021–2031. 2 indexed citations

Hara, Ryujiro, Makoto Onizuka, Eri Kikkawa, et al.. (2021). Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of Hematology. 100(10). 2479–2486. 3 indexed citations

Hara, Ryujiro, Hiroshi Kawada, Yara Yukie Kikuti, et al.. (2021). A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor. International Journal of Hematology. 113(4). 606–610. 3 indexed citations

Hara, Ryujiro, Makoto Onizuka, Kaito Harada, et al.. (2020). The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury. Clinical Lymphoma Myeloma & Leukemia. 21(4). e321–e327. 5 indexed citations

Ohmachi, Ken, Michinori Ogura, Youko Suehiro, et al.. (2019). A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. International Journal of Hematology. 109(6). 657–664. 28 indexed citations

Sakai, Rika, Ken Ohmachi, Fumiaki Sano, et al.. (2019). Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Annals of Hematology. 98(9). 2131–2138. 3 indexed citations

Ogura, Michinori, Ken Ohmachi, Ritsuro Suzuki, et al.. (2017). A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG). Blood. 130. 2789–2789. 1 indexed citations

10.

Hara, Ryujiro, Makoto Onizuka, Eri Kikkawa, et al.. (2017). NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib. International Journal of Hematology. 106(5). 666–674. 21 indexed citations

11.

Matsushita, Hiromichi, Ken Ohmachi, Minoru Kojima, et al.. (2015). Four hepatosplenic T-cell lymphoma cases of Japanese patients. Leukemia Research Reports. 5. 3–6. 2 indexed citations

12.

Amaki, Jun, Makoto Onizuka, Ken Ohmachi, et al.. (2015). Single nucleotide polymorphisms of cytarabine metabolic genes influence clinical outcome in acute myeloid leukemia patients receiving high-dose cytarabine therapy. International Journal of Hematology. 101(6). 543–553. 16 indexed citations

13.

Watanabe, Takashi, Masato Mitsuhashi, M. Sagawa, et al.. (2015). Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma. PLoS ONE. 10(6). e0128662–e0128662. 4 indexed citations

14.

Ogawa, Yoshiaki, Michinori Ogura, Kensei Tobinai, et al.. (2015). A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International Journal of Hematology. 103(1). 25–33. 11 indexed citations

15.

Chihara, Dai, Naoki Asano, Ken Ohmachi, et al.. (2015). Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Annals of Oncology. 26(5). 966–973. 34 indexed citations

16.

Watanabe, Takashi, Masato Mitsuhashi, M. Sagawa, et al.. (2013). Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer Journal. 3(10). e150–e150. 5 indexed citations

17.

Ohmachi, Ken, Kensei Tobinai, Yukio Kobayashi, et al.. (2011). Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin’s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Annals of Oncology. 22(6). 1382–1391. 25 indexed citations

18.

Ogura, Michinori, Kiyoshi Ando, Masafumi Taniwaki, et al.. (2011). Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non‐Hodgkin’s lymphoma⁶. Cancer Science. 102(9). 1687–1692. 19 indexed citations

19.

Ohmachi, Ken, Kiyoshi Ando, Michinori Ogura, et al.. (2010). Multicenter phase II study of bendamustine for relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma and mantle cell lymphoma. Cancer Science. 101(9). 2059–2064. 50 indexed citations

20.

Tsuboi, Kosuke, Kenji Kishi, Ken Ohmachi, et al.. (2003). Multivariate analysis of risk factors for hemorrhagic cystitis after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 32(9). 903–907. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact